Would accelerated FDA approvals attract more investors? Print
By Staff and Wire Reports   
Thursday, 03 May 2012 10:53
Congress appears poised this year to deliver on years of lobbying by industry to speed up reviews of new drugs and cut regulatory red tape.

That helping hand alone, however, isn’t likely enough to draw investors, still shell-shocked by the recession, back into funding new biopharma startups and early-stage companies.

Several bills promising fast relief for biopharma are pending in Congress. Chief among them is the fifth authorization of the Prescription Drug User Fee Act (PDUFA V). Faster action on drug applications is the goal of the Faster Access to Specialized Treatments (FAST) Act introduced in the House of Representatives; the Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act introduced in the Senate; and another Senate bill, the Advancing Breakthrough Therapies for Patients Act of 2012.

Among the claims made in support of the measures is that they will help draw venture capitalists and other traditional investors back to biopharma companies, thawing the long-chilly investment climate knocked cold by the Great Recession and weak recovery of the past five years. Maybe so, but it won’t likely be as quickly as startups are hoping for.

Read the Rest of this Report

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus